What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

Immunotherapy advances in lymphoma, treating IDH1-mutated acute myeloid leukemia (AML), and managing COVID-19 in patients with blood disorders comprise some of the major topics that will be discussed at the American Society of Hematology (ASH) Annual Meeting and Exposition taking place Dec. 11 through 14. Leaders from ASH discussed the research during a preview webinar with media on Nov. 22.